Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complement and glomerulonephritis: new insights.

Daniel Turnberg1, H Terence Cook

  • 1Department of Nephrology, Charing Cross Hospital, London, UK.

Current Opinion in Nephrology and Hypertension
|April 12, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complement inhibitors and B cell-modifying agents for IgA nephropathy-a Kidney Disease: Improving Global Outcomes (KDIGO) commentary.

Kidney international·2026
Same author

Characterizing the NIH Activity and Chronicity Indices in 2 Independent Lupus Nephritis Cohorts.

Kidney international reports·2026
Same author

Biomarkers in the Management of Complement-Mediated Kidney Diseases in the Era of Complement Therapeutics.

Clinical journal of the American Society of Nephrology : CJASN·2025
Same author

Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV).

Kidney international·2025
Same author

KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV).

Kidney international·2025
Same author

Kidney Complement Immunohistochemistry in Thrombotic Microangiopathy Subtypes.

Kidney international reports·2025
Same journal

Primary prevention of chronic kidney disease in type 2 diabetes mellitus with sodium-glucose cotransporter 2 inhibitors.

Current opinion in nephrology and hypertension·2026
Same journal

Financial and policy challenges of delivering kidney replacement therapies in resource-limited settings.

Current opinion in nephrology and hypertension·2026
Same journal

The role of kir4.1/Kir5.1 in mediating the effect of angiotensin-II on Na-Cl-cotransporter.

Current opinion in nephrology and hypertension·2026
Same journal

Role of the calcium-sensing receptor in regulating calcium transport in the thick ascending limb.

Current opinion in nephrology and hypertension·2026
Same journal

Social determinants of chronic kidney disease: from association to clinical and population action.

Current opinion in nephrology and hypertension·2026
Same journal

Advancing science and care in CKD-MBD: the layered path to legacy.

Current opinion in nephrology and hypertension·2026
See all related articles

The complement system significantly impacts glomerular diseases. Targeting complement pathways offers promising therapeutic strategies for kidney conditions like lupus nephritis and atypical hemolytic uremic syndrome.

Area of Science:

  • Nephrology
  • Immunology
  • Molecular Biology

Background:

  • The complement system is crucial in innate immunity and inflammation.
  • Its dysregulation is increasingly implicated in various glomerular diseases.
  • Understanding complement's role is vital for developing targeted therapies.

Purpose of the Study:

  • To review recent advances in understanding complement's role in glomerular diseases.
  • To highlight the therapeutic potential of targeting complement pathways.

Main Methods:

  • Review of current literature on complement in glomerular diseases.
  • Analysis of experimental models of kidney inflammation.
  • Synthesis of findings on complement pathways and regulatory proteins.

Related Experiment Videos

Main Results:

  • Classical complement pathway protects against autoimmunity; alternative pathway exacerbates glomerular injury.
  • Anti-C1q antibodies are pathogenic in lupus nephritis.
  • Complement activation contributes to tubulointerstitial injury and myofibroblast activation.
  • Defects in complement regulatory proteins (Factor H, CD46) are linked to atypical hemolytic uremic syndrome.

Conclusions:

  • Targeting the complement system presents a promising therapeutic avenue for glomerular diseases.
  • Developing therapies requires careful consideration of complement's pro- and anti-inflammatory roles.
  • New drugs targeting complement are emerging, offering hope for improved patient outcomes.